The Research Clause Samples
The Research clause defines the scope and nature of the research activities to be conducted under the agreement. It typically outlines what specific research will be performed, the objectives or deliverables expected, and any relevant methodologies or timelines. For example, it may specify that a university will investigate a particular scientific question using agreed-upon techniques within a set timeframe. This clause ensures that both parties have a clear understanding of the research expectations, thereby minimizing misunderstandings and aligning efforts toward common goals.
POPULAR SAMPLE Copied 1 times
The Research. 2.1. In addition to the Initial Research Program, the Company shall finance performance of a Subsequent Research Program in accordance with a Subsequent Research Budget during the Subsequent Research Period or any amendments thereof as may be agreed upon by the Company and Yissum.
2.2. The Research conducted pursuant to the Initial Research Program shall be governed by the R&O Agreement and the Research to be conducted pursuant to the Subsequent Research Program shall be governed by this Agreement. The Research shall be conducted under the supervision of the Researcher Should the Researcher be unable to complete the Research for any reason, Y▇▇▇▇▇ shall notify the Company of the identity of a suitable replacement researcher. If the Company does not object in writing to the replacement researcher on reasonable grounds within twenty (20) days of this notification, the substitute researcher shall be deemed acceptable to the Company. Alternatively, the Company shall have the right to terminate the Research, provided that (i) no monies paid to Yissum for the Research in accordance with the Research Budget and pursuant to the schedule set forth in Appendix B, will be refundable; and (ii) the Company shall be responsible for the payment of any accrued fees and expenses due to Yissum based on work duly performed up to the date of termination and those irrevocable commitments that were part of the Research Budget and entered into by Yissum prior to having received the Company’s written notice of termination.
2.3. For the avoidance of doubt, should the Company wish to place its employees in the laboratories of the Researcher on any campus of the University in connection with the Research or any other aspect of this Agreement it may do so after executing a separate agreement with Yissum setting out the terms of such placement.
2.4. As compensation to Yissum for the performance of the Subsequent Research Program, subject to any earlier termination of the Subsequent Research Program pursuant to Section 2.2 above, the Company shall pay Yissum the total sum of (*******************) as follows: (i) the first installment shall be paid on the Effective Date; (ii) the second installment shall be paid within three (3) months of the Effective Date; and (iii) the third installment shall be paid within six (6 months of the Effective Date (iv) the fourth installment shall be paid within nine (9) months of the Effective Date; (v) the fifth installment shall be paid within twelve (...
The Research. There is a significant body of research that supports the use of personal, digital learning devices in the classroom. The Horizon Report (▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/publications/2014-horizon-report-k12) investigates three areas of the adoption of technology in education. They include: Key Trends, Significant challenges, and Important Developments. One of the key trends that is identified in the report is a shift towards deeper learning approaches that involves “the delivery of rich core content to students in innovative ways that allow them to learn and then apply what they have learned… As technologies such as tablets and smartphones are more readily accepted in schools, educators are leveraging these tools, which students already use, to connect the curriculum with real life applications. These active learning approaches are decidedly more student-centered, allowing learners to take control of how they engage with a subject…” (p.
The Research. 2.1 The Parties shall undertake the Allocated Work as specified in the Call Specifications and the Work Plan. The Contractor shall be bound mutatis mutandis by the terms and conditions of the Head Contract, which form part of this Subaward; except that provisions of the Head Contract that are particular to Lancaster or the Principal Investigator shall apply only to Lancaster.
2.2 The Allocated Work shall be performed by the persons named in the Work Plan, where relevant.
2.3 In respect of the Allocated Work, the Contractor will use its reasonable endeavours to provide adequate facilities; to obtain any requisite materials, equipment and personnel; and to carry out their work diligently. Although the Contractor will use its reasonable endeavours to perform the Allocated Work, the Contractor does not undertake that the Allocated Work carried out under or pursuant to this Subaward will lead to any particular result, nor is the success of such work guaranteed.
2.4 The Contractor will use reasonable endeavours to meet the milestones and deadlines set out in the Work Plan at Schedule 1, and in accordance with any Key Performance Indicators specified in the Call Specifications. In the event that there is any conflict between the Work Plan and the Call Specifications, the Call Specifications will prevail.
2.5 The Parties will comply with all requirements of the relevant Institutional Ethics Committee in respect of the Allocated Work, and shall also refer a copy of all applications to NABS+’s Security Research Ethics Committee for consideration as soon as is reasonably practical. Each Party will comply with the requirements of the Security Research Ethics Committee.
The Research. 2.1. The Company hereby undertakes to finance performance of the Research in accordance with the Research Program or any amendment thereof. Such financing, subject to any earlier termination of the Research pursuant to Section 2.2 below, shall be one hundred fifty thousand US Dollars [US $150,000 which includes HUJI overhead in effect at the Effective Date (the “Research Fee”) plus value added tax (VAT), if applicable, payable in accordance with the payment schedule mutually agreed upon by the Parties which will include among other things periodic payments tied to the achievement of pre-defined research milestones; all as set forth in Appendix B. For the avoidance of doubt, the Research Program will not begin until the Company has paid the first payment set forth in Appendix B. Because the allocation of expenses in the Research Budget is based on expected expense categories and an expected allocation of specific expenses within each category, such categories and the allocation of expenses among the various expense categories may be modified by the Researcher(s) where reasonably necessary or appropriate during the Research Period, it being agreed, however that the aggregate Research Fee shall not be increased without the written consent of the Company and shall not otherwise adversely affect the Company and the Company shall be provided with written notice of such reallocation. Payments may be made by check or by wire transfer to the following account: Name of Bank: Hapoalim Bank Key: 12 Bank’s Address: ▇▇▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇, ▇▇▇▇▇▇ Branch: Holon Service Center - 436 Bank Account Number: 12-436-142-155001 Swift Code: ▇▇▇▇▇▇▇▇ IBAN: ▇▇▇▇-▇▇▇▇-▇▇▇▇-▇▇▇▇-▇▇▇▇-▇▇▇ (for payment from Europe only) The Company shall always use the payment information provided above. The Company shall not accept any changes in respect of the payment route or bank account details that are received via email, facsimile or by other means of communication, including, without limitation, any invoice or other written request for payment, unless such changes are set forth in an amendment to this Agreement on the letterhead of Yissum signed by its Chief Financial Officer or Controller. If the Company breaches this provision, it shall bear any financial loss or other consequences arising therefrom and shall indemnify Yissum for any such loss or damages that may be incurred by Yissum.
2.2. The Research shall be conducted by and under the supervision of the Researcher, together with HUJ staff cho...
The Research. 2.1 In consideration of the first Work Order the parties agree that if, at any time during the Term, it is agreed that Quotient Clinical will perform any particular trial, study and/or services for the Customer, a document in substantially the form set out in schedule 1 will be completed and issued by Quotient Clinical in relation to such trial, study and/or services, and will be signed by both parties. Each such Work Order will constitute a separate contract between the parties for the performance by Quotient Clinical of the relevant Research, and the payment by the Customer of the amounts set out in the relevant Proposal (and the performance by the Customer of its other obligations), in accordance with the terms of this Agreement and the relevant Work Order (to the exclusion of any other terms and/or conditions which the Customer may attempt or purport to impose).
2.2 Quotient Clinical shall carry out all Research in accordance with the relevant Clinical Protocol and with due skill and care in accordance with industry best practice and strictly in accordance with the Proposal, the Regulations and all other applicable laws, Good Clinical Practice and Good Manufacturing Practice. Quotient Clinical must inform Customer within 24 hours of any serious adverse events and significant deviations from, or breaches of the standards applied to the Services, to enable Customer to meet its requirements for reporting such events to the applicable Regulatory Authority.
2.3 All services to be provided by Quotient Clinical under this Agreement and any Work Order will be deemed to be provided at the Customer’s request and the Customer accepts that it is responsible for verifying that those services are suitable for its own needs.
2.4 The Customer may during this Agreement inspect and/or audit Quotient Clinical’s performance of any Research on giving Quotient Clinical at least 48 hours written notice. The Customer shall use its reasonable endeavours not to cause any disruption to Quotient Clinical’s business in carrying out such inspection or audit.
2.5 The Customer shall ensure that its employees co-operate fully with Quotient Clinical and any Service Providers in relation to the provision of any Research (including without limitation complying with Quotient Clinical’s normal and reasonable codes of staff and security practice). The Customer shall comply with its obligations as set out in any Proposal in a timely manner.
2.6 The Customer shall provide to Quotient Clinical...
The Research. The Company and FFB shall collaborate on a funded research program to support the Investigator in the performance of the Research. In supporting the Research, the parties shall take the following actions:
(a) Subject to the terms and conditions of this Agreement, including without limitation, Sections 1(d) and 1(e), the Company shall provide sufficient quantities of the Study Drug to the Investigator to permit him to perform the Research.
(b) Both parties shall keep each other fully informed regarding the progress and results of the Research to the extent that it receives such information from the Investigator and shall provide to each other a copy of the final report on the Research prepared by the Investigator (“Final Report”).
(c) FFB shall fund the Research for the total amount specified in Attachment B attached hereto and incorporated by reference (the “Budget”). FFB shall pay the money to the Institution according to a schedule agreed upon by FFB and the Institution. In the event that the Investigator becomes unavailable to conduct the Research, and the Company and FFB do not reach agreement regarding a new investigator, the Company may terminate this Agreement.
(d) It is understood and agreed that FFB’s obligations to fund the Research is conditioned upon the Investigator and the Institution entering into the CTA. In the event that the Investigator and the Institution do not enter into such a CTA with the Company within ninety (90) days after the execution of this Agreement, this Agreement shall terminate.
(e) Each party agrees that it will provide the other party with a copy of any Research-related agreement, such as the CTA or a grant or funding agreement, that it enters into with the Institution or Investigator.
The Research. 2.1 The Company undertakes to fund and pursue the Initial Research in accordance with the terms contained herein, and to make its reasonable commercial efforts to actively pursue the performance of the Research, and to secure funding for the Research. The parties hereto acknowledge that the administration of the Company’s research and development activities in Israel shall be performed by Biogal Israel, as a sublicensee of the Company, pursuant to the terms and conditions of the Sublicense Agreement executed concurrently with this Agreement by and between the Company and Biogal Israel, attached hereto as Attachment E. The Parties hereto acknowledge that the financing of the Company’s research and development activities in Israel shall be performed by the Company and that the Company and Biogal Israel shall be jointly and severally liable for such financing. The Initial Research shall be performed at the Institute and certain hospitals and medical institutes as set forth in the Initial Research Program, and within the framework of the Initial Research Budget. The Initial Research Budget with regard to the Research at the Institute shall consist of one thirteen (13) month period and payments for the performance of the Research at the Institute shall be made in four installments, as follows (i) for the first nine-month period of the Initial Research, payment shall be made for each three month period in advance; and (ii) for the last four month period of the Initial Research, payment shall be made in one installment in advance. The Initial Research Budget with regard to the Initial Clinical Research shall consist of one eighteen (18) month period, and payments for the performance of the Initial Research Budget shall be made for each three (3) month period in advance.
2.2 Subject to the terms and conditions hereof, Yeda undertakes to procure the performance of the laboratory portion of the Initial Research designated to be performed at the Institute according to the Initial Research Program (the “Research at the Institute”), under the supervision of P▇▇▇. ▇▇▇▇▇-▇▇▇▇▇ provided however that the fact that P▇▇▇. ▇▇▇▇▇-▇▇▇▇▇ shall cease to be available for the supervision of the performance of the Research at the Institute shall not constitute a breach of this Agreement by Yeda. In such event, Yeda shall make its reasonable effort to find from amongst the scientists of the Institute a replacement scientist acceptable to the Company (such acceptance to be in writing,...
The Research. 4.1. The Parties shall undertake the Research, as described in Section 3 of the Contract including any modifications, deletions or expansions approved in writing by all Parties, in accordance with the provisions of this Agreement and in such a way as to enable the Lead Party to comply with the Lead Party’s obligations under the Contract. The Parties to this Agreement agree to be bound by the terms and conditions of the Contract, which form part of this Agreement; except that provisions of the Contract that exclusively apply to Lead Party shall apply only to the Lead Party. In the event of any conflict between the terms of this Agreement and the terms of the Contract, then the terms of the Contract will prevail. For the avoidance of doubt, the payment terms agreed between the Lead Party and the Collaborator in a Research Budget Agreement will prevail over the payment terms in clause 4.1 of the Contract.
4.2. Each Party undertakes to take part in the efficient implementation of the Research, and to cooperate, perform and fulfil, promptly and on time, all of its obligations under the Agreement and as may be reasonably required from it and in a manner of good faith as prescribed by Applicable Law.
4.3. The Research shall be performed by or under the direction and supervision of the LMIC Joint Lead Investigator and the UK Joint Lead Investigator as listed in the Application.
4.4. In respect of the Research, each Party will use its reasonable endeavours to provide adequate facilities; to obtain any requisite materials, equipment and personnel; and to carry out the work diligently and to the highest academic standards, within the scope allowed by its funding. Although each Party will use its reasonable endeavours to perform the Research, no Party undertakes that work carried out under or pursuant to this Agreement will lead to any particular result, nor is the success of such work guaranteed. For the avoidance of doubt, nothing in this Clause purports to permit any Party to reverse engineer or otherwise analyse any of the materials provided to it under this Agreement except in accordance with the provisions of this Agreement and to the extent applicable by Applicable Law.
4.5. In accordance with Clause 3.4 of the Contract, the Parties must ensure that the Research is:
4.5.1. primarily relevant to near-term or long-term benefits to the health or prosperity of low or middle income countries as defined by the OECD from time to time;
4.5.2. performed in accordance wi...
The Research. Tufts MC agrees to use its reasonable efforts to perform the research program described in Exhibit A (the “Research”).
The Research. 1.1 The College’s contact for the Research shall be ▇▇. ▇▇ ▇▇▇▇ in its School of Genetics & Molecular Medicine (the ‘Investigator’). If ▇▇. ▇▇ ▇▇▇▇ is unable or unwilling to continue the supervision of the Research on behalf of the College, the College shall promptly notify the Company, and advise it of a suitable successor within 60 days thereafter; the Company shall not unreasonably decline to accept the choice of a successor selected in this way but if it can demonstrate reasonable grounds for not wishing to accept the choice, then the Company may terminate this Agreement in accordance with the terms set out in clause 8 below.
1.2 The Company’s contact for the Research shall be ▇▇. ▇▇▇▇▇ ▇▇▇▇▇▇▇-Vives. If ▇▇. ▇▇▇▇▇ ▇▇▇▇▇▇▇-Vives is unable or unwilling to continue the supervision of the Research on behalf of the Company, the Company shall promptly notify the College, and advise it of a suitable successor within 60 calendar days thereafter; the College shall not unreasonably decline to accept the choice of a successor selected in this way but if it can demonstrate reasonable grounds for not wishing to accept the choice, then the College may terminate this Agreement in accordance with the terms set out in clause 8 below. The parties must give notice as soon as is practicable to the other party should there be any changes to the Company or College staff so that the Research will not be negatively affected by such unforeseen changes
1.3 Each Party undertakes to supply the levels of data, manpower, materials, resources and commitment identified as its contribution to the Research in Schedule 1, and shall endeavour to ensure the accuracy of all such data and promptly to correct any error therein of which it becomes aware. For the avoidance of doubt, any data, information or materials which one Party supplies to the other in the course of the Research shall represent Confidential Information and/or Background IP (as each such term is defined elsewhere herein) belonging to that Party. The College has received funding from ▇▇▇▇▇ U.K. for the project. The funding and budget for the Research does not include the costs of the SkinGun™, the disposable attachments, the Company’s expertise and assistance in anything related to the cell delivery. The College does not have any publishing, patent, or intellectual property obligations to ▇▇▇▇▇ U.K. which may affect this Research.
1.4 If either Party reasonably believes that the Research or the way in which a Party is under...